Epsilon M&A Deal Report - Koninklijke Sanders (Royal Sanders)

Transaction Multiples for the Valuation of Private Companies

Private Group led by 3i Group > Koninklijke Sanders (Royal Sanders)

Announced Date : 12 February 2018

Type : SBO (Secondary Buy Out) ,Exit

Deal Value : Yes

Acquirer : Private Group led by 3i Group

Target: Koninklijke Sanders (Royal Sanders)

Target Country: Netherlands

Sector of activity : Health, Pharmaceuticals & Biotechnology

Business Description :

> Founded in 1851, Koninklijke Sanders BV (Royal Sanders) is an European manufacturer and d ...

No EMAT : 94516

Transaction multiples available

	EV/Sales	EV/Gross Profit	EV/EBITDA	EV/EBIT	Eq/PBT	P/E	Price to Book
Historic
Current

: Multiple available

n.s : Multiple calculated, but not significant

Rating *

Source: Epsilon Research / EMAT

Comparable Transactions

Number of EMAT Reports : (Health, Pharmaceuticals & Biotechnology) = 1228

Example of comparable transactions on EMAT (same sub-sector):

Date	Acquirer	Target	Country	Multiples	See details
03/09/2018	The Hut Group (THG)	Acheson & Acheson	United Kingdom	**
04/01/2019	Health and Happiness (H&H) International	Aurelia Probiotic Skincare	United Kingdom	*

Source: Epsilon Research / EMAT

View Report

This report is accessible on EMAT, the reference database for private company acquisition multiples

Example of EMAT Report : click here

View Complete Report

About Epsilon Research

Epsilon Research is an independent research and financial analysis bureau, and the reference source of transaction multiples for the valuation of private companies through its EMAT database.

Sectors covered by our analysts

Studies & indices published by Epsilon Research Register to receive (free) publications updates

EMAT Report

Each EMAT Report includes the detailed analysis of the transaction: deal rationale and structure, target business lines and financials (restated), valuation multiples (calculation and analysis).

Subscribe to EMAT database